GLP-1 References

Summary: Every clinical claim on GLP1 Alpha traces to a primary source. This page consolidates all 224 references cited across the site, grouped by source type, with direct links so you can verify any number we publish.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Sources are grouped by category rather than by article. The strongest evidence comes from FDA prescribing information and the major trial papers in the New England Journal of Medicine, which appear first. Academic medical centers and government health resources fill in clinical context. News and legal analyses document the regulatory and pricing developments around the drug class. To see the references that were used in a specific article, visit that article's page directly.

FDA labels and safety communications
  1. U.S. Food and Drug Administration. FDA approves new medication for chronic weight management (tirzepatide / Zepbound). FDA News Release, 2023. fda.gov
  2. U.S. Food and Drug Administration. Highlights of Prescribing Information: Ozempic (semaglutide) injection. Novo Nordisk / FDA, 2024. accessdata.fda.gov
  3. U.S. Food & Drug Administration. Ozempic (semaglutide) Injection Prescribing Information, NDA 209637. accessdata.fda.gov, 2025. accessdata.fda.gov
  4. U.S. Food & Drug Administration. Rybelsus (semaglutide) Tablets Prescribing Information, NDA 213051. accessdata.fda.gov, 2025. accessdata.fda.gov
  5. U.S. Food & Drug Administration. Wegovy (semaglutide) Injection Prescribing Information, NDA 215256. accessdata.fda.gov, 2025. accessdata.fda.gov
  6. U.S. Food & Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH. FDA News, August 15, 2025. fda.gov
  7. U.S. Food & Drug Administration. Rybelsus Tablets, Highlights of Prescribing Information. accessdata.fda.gov, 2024. accessdata.fda.gov
  8. U.S. Food & Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. FDA Drug Alerts, 2025. fda.gov
  9. U.S. Food and Drug Administration. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. FDA Press Announcement, 2022. fda.gov
  10. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. FDA Press Announcement, December 2024. fda.gov
  11. U.S. Food and Drug Administration. Saxenda (liraglutide) approval, December 2014. FDA news release
  12. U.S. Food and Drug Administration. Questions and Answers: Safety Requirements for Victoza (liraglutide). fda.gov
  13. U.S. Food and Drug Administration. FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes. Press announcement, 23 December 2024. fda.gov
  14. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
  15. U.S. Food and Drug Administration. Ozempic (semaglutide) injection, prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl
  16. U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection, prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl
  17. U.S. Food and Drug Administration. Wegovy (semaglutide) injection, prescribing information, including 2023 pediatric supplement. accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl
  18. U.S. Food and Drug Administration. Saxenda (liraglutide) injection 3 mg, prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl
  19. U.S. Food and Drug Administration. Victoza (liraglutide) injection, prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl
  20. U.S. Food & Drug Administration. "Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss." fda.gov
  21. US Food and Drug Administration. "Compounding and the FDA: Questions and Answers." fda.gov
  22. US Food and Drug Administration. "Compounding Laws and Policies." fda.gov
  23. US Food and Drug Administration. "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A." fda.gov

New England Journal of Medicine

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine, 2023. nejm.org
  2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine, 2024. nejm.org
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. nejm.org
  4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. nejm.org
  5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine, 2023. nejm.org
  6. Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine, 2022. nejm.org
  7. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). New England Journal of Medicine, 2025. nejm.org
  8. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine, 2023. nejm.org
  9. Knop FK, Aroda VR, do Vale RD, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine, 2025. nejm.org
  10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. nejm.org
  11. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. nejm.org
  12. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. nejm.org
  13. Marso SP, et al. LEADER trial cardiovascular outcomes summary. NEJM 2016. nejm.org
  14. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med 2024;391:109-121. doi:10.1056/NEJMoa2403347
  15. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. doi:10.1056/NEJMoa2404881
  16. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
  17. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med 2019;381:841-851. doi:10.1056/NEJMoa1901118
  18. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med 2025;392:427-437. doi:10.1056/NEJMoa2410027
  19. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. doi:10.1056/NEJMoa2401943
  20. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). N Engl J Med 2024;391:1573-1583. doi:10.1056/NEJMoa2403664

Other peer-reviewed journals

  1. Zhao F, Zhou Q, Cong Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Nature Signal Transduction and Targeted Therapy, 2024. nature.com
  2. BMJ Editorial Team. Weight regain after cessation of medication for obesity. BMJ, 2025. bmj.com
  3. Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, 2022. jamanetwork.com
  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA, 2021. jamanetwork.com
  5. Garvey WT, Batterham RL, Bhatta M, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine, 2022. nature.com
  6. Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE). The Lancet, 2025. thelancet.com
  7. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology, 2024. jamanetwork.com
  8. Cummings JL, Atri A, Feldman HH, et al. Efficacy and Safety of Oral Semaglutide 14 mg in Early-Stage Symptomatic Alzheimer's Disease (evoke and evoke+). The Lancet, 2026. thelancet.com
  9. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138-150. JAMA
  10. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. nature.com
  11. Levi J, Wang J, Venter F, Hill A. "Estimated minimum prices and lowest available national prices for antiobesity medications." JAMA Network Open. 2023. jamanetwork.com
  12. JAMA Health Forum. "Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists." January 2025. jamanetwork.com

PubMed and PubMed Central

  1. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). PMC, 2019. pmc.ncbi.nlm.nih.gov
  2. Nauck MA, Meier JJ. GIP and GLP-1, the two incretin hormones: similarities and differences. PMC, 2014. pmc.ncbi.nlm.nih.gov
  3. Drucker DJ, Holst JJ. The GLP-1 journey: from discovery science to therapeutic impact. PMC, 2024. pmc.ncbi.nlm.nih.gov
  4. StatPearls. Glucagon-Like Peptide-1 Receptor Agonists. NCBI Bookshelf, 2024. ncbi.nlm.nih.gov
  5. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism, 2021. PMC8346189. pmc.ncbi.nlm.nih.gov
  6. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas: cAMP, PKA, Epac2, and insulin granule exocytosis. PMC3118608. pmc.ncbi.nlm.nih.gov
  7. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes. PMC, 2021. pmc.ncbi.nlm.nih.gov
  8. Mann JFE, Rossing P, Bakris G, et al. FLOW trial design and rationale. Nephrology Dialysis Transplantation, 2023. PMC10469096. pmc.ncbi.nlm.nih.gov
  9. Yamamoto K, Iwasaki Y, Maejima Y, et al. Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons. Peptides, 2018. PubMed 30081042. pubmed.ncbi.nlm.nih.gov
  10. Aroda VR, Blonde L, Pratley RE. The Oral Semaglutide Experience: SNAC technology and clinical practice. PMC10788673, 2024. pmc.ncbi.nlm.nih.gov
  11. Hall S, Isaacs D, Clements JN. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clinical Pharmacokinetics, 2018. ncbi.nlm.nih.gov
  12. Jensen L, Helleberg H, Roffel A, et al. Pharmacokinetics and Tolerability of Semaglutide in People with Hepatic Impairment. Diabetes, Obesity and Metabolism, 2018. ncbi.nlm.nih.gov
  13. Aroda VR, Ahmann A, Cariou B, et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1-7 Trials. Diabetes & Metabolism, 2019. pubmed.ncbi.nlm.nih.gov
  14. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and Safety of Once-Weekly Semaglutide 1.0 mg vs Once-Daily Liraglutide 1.2 mg (SUSTAIN 10). Diabetes & Metabolism, 2020. pubmed.ncbi.nlm.nih.gov
  15. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). New England Journal of Medicine, 2025. pubmed.ncbi.nlm.nih.gov
  16. Farzam K, Patel P. Tirzepatide. StatPearls, NCBI Bookshelf, 2024. ncbi.nlm.nih.gov
  17. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024. pubmed.ncbi.nlm.nih.gov
  18. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine, 2024. pubmed.ncbi.nlm.nih.gov
  19. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). New England Journal of Medicine, 2024. pubmed.ncbi.nlm.nih.gov
  20. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. PMC5358074
  21. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed 27295427
  22. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. pubmed.ncbi.nlm.nih.gov
  23. SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials. J Endocr Soc. 2024. pmc.ncbi.nlm.nih.gov
  24. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial. Lancet Diabetes Endocrinol. 2025. pubmed.ncbi.nlm.nih.gov
  25. Conte C, et al. Multiorgan effects of glucagon-like peptide-1 receptor agonists in obesity: implications for body composition and lean mass. Nutrients. 2024;16(11):1668. PMID: 38892559
  26. Phillips SM, Chevalier S, Leidy HJ. Protein "requirements" beyond the RDA: implications for optimizing health. Applied Physiology, Nutrition, and Metabolism. 2016;41(5):565-572. PMID: 26960445
  27. Quddos F, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports. 2023;13:20998. PMID: 38017205
  28. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PMID: 35441470
  29. Academy of Nutrition and Dietetics. Position Paper: Interventions for the Treatment of Overweight and Obesity in Adults. Journal of the Academy of Nutrition and Dietetics. 2016;116(1):129-147. PMID: 26718656
  30. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Considerations for Skeletal Muscle Mass and Functional Capacity. Diabetes Care. 2024;47(10):1718-1730. PMID: 38687506
  31. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. PMC, 2024. PMC12536186
  32. Academy of Nutrition and Dietetics. Plant-Based Diet Position Paper. Journal of the Academy of Nutrition and Dietetics. 2016;116(12):1970-1980. PMID: 27886704
  33. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39937469

ClinicalTrials.gov

  1. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity or Overweight (TRIUMPH-1). NCT05929066. clinicaltrials.gov
  2. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). NCT05931367. clinicaltrials.gov
  3. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (TRIUMPH-2). NCT05929079. clinicaltrials.gov
  4. ClinicalTrials.gov. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). NCT06383390. clinicaltrials.gov
  5. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) on Renal Function in Adults With Obesity and Chronic Kidney Disease (TRANSCEND-CKD). NCT05936151. clinicaltrials.gov

Other US government health resources

  1. MedlinePlus. Semaglutide Injection. U.S. National Library of Medicine, 2024. medlineplus.gov
  2. National Library of Medicine. Tirzepatide Injection: MedlinePlus Drug Information. MedlinePlus, 2024. medlineplus.gov
  3. MedlinePlus. Liraglutide Injection. U.S. National Library of Medicine. medlineplus.gov
  4. DailyMed. Victoza (liraglutide injection) label. National Library of Medicine. dailymed.nlm.nih.gov
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity. NIDDK, 2023. niddk.nih.gov
  6. Centers for Medicare & Medicaid Services. "Medicare GLP-1 Bridge." cms.gov
  7. Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Program." cms.gov
  8. Centers for Medicare & Medicaid Services. "BALANCE Model: Better Approaches to Lifestyle and Nutrition for Comprehensive Health." cms.gov

Academic medical centers

  1. Cleveland Clinic. GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic, 2024. my.clevelandclinic.org
  2. Harvard Health Publishing. How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. Harvard Medical School, 2024. health.harvard.edu
  3. WMCHealth. Beyond the Ozempic Buzz: How GLP-1s Actually Work. Westchester Medical Center Health Network, 2024. wmchealth.org
  4. Stanford Medicine. One in 10 people may have resistance to GLP-1 diabetes drugs (PAM gene variants). Stanford News, 2026. med.stanford.edu
  5. Mayo Clinic. Semaglutide (Subcutaneous Route): Description and Brand Names. Mayo Clinic, 2026. mayoclinic.org
  6. Cleveland Clinic. Tirzepatide Injection. my.clevelandclinic.org, 2024. clevelandclinic.org
  7. Mancini MC, de Melo ME. Liraglutide (Saxenda) for Weight Loss. Am Fam Physician. 2016;94(2):161-162. aafp.org
  8. Mayo Clinic. Liraglutide (subcutaneous route): description and brand names. mayoclinic.org
  9. Cleveland Clinic. Liraglutide injection for weight management. my.clevelandclinic.org
  10. Mayo Clinic. Semaglutide (oral route) description and dosing. mayoclinic.org/drugs-supplements/semaglutide-oral-route
  11. Harvard Health Publishing. GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more. Harvard Medical School, 2024. health.harvard.edu
  12. Cleveland Clinic Health Essentials. Can Certain Foods Impact Your Ozempic Side Effects? (Beth Czerwony, RD, LD). 2024. health.clevelandclinic.org

Medical specialty societies

  1. American Diabetes Association. Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Blood Sugar Reductions and Weight Loss. diabetes.org, 2021. adameetingnews.org

Novo Nordisk and brand resources

  1. Novo Nordisk. Wegovy (semaglutide) Prescribing Information and Patient Site. Novo Nordisk, 2026. wegovy.com
  2. Novo Nordisk. Ozempic (semaglutide) Prescribing Information and Patient Site. Novo Nordisk, 2026. ozempic.com
  3. WebMD. Ozempic (Semaglutide): Uses, Side Effects, Interactions. WebMD, 2026. webmd.com
  4. Pharmaceutical Executive. FDA Approves Novo Nordisk's Wegovy Pill for Weight Management. PharmExec, December 2025. pharmexec.com
  5. Drugs.com. Semaglutide Prices and Coupons. Drugs.com, 2026. drugs.com
  6. NovoCare. Wegovy Self-Pay through NovoCare Pharmacy. Novo Nordisk, 2026. novocare.com
  7. GoodRx. 7 Rybelsus Drug Interactions to Know Before Taking It. GoodRx, 2026. goodrx.com
  8. Novo Nordisk. How to Use Ozempic Pen: Dosing and Storage. Ozempic.com, 2026. ozempic.com
  9. NovoCare. Savings Offer Program for Wegovy. Novo Nordisk, 2026. novocare.com
  10. Hikma Pharmaceuticals. Hikma receives FDA approval and launches the generic version of Victoza (liraglutide) in the US. Press release, 26 December 2024. hikma.com
  11. Novo Nordisk. How to use Ozempic pen. ozempic.com/how-to-take/ozempic-dosing
  12. Second Nature. Wegovy and chronic kidney disease, pregnancy and lactation guidance based on FDA label. secondnature.io
  13. Healthline. Ozempic Diet Plan: A List of Foods to Eat and What to Avoid. 2024. healthline.com
  14. Medical News Today. What vitamins to take with Ozempic (semaglutide) and why. 2024. medicalnewstoday.com
  15. Novo Nordisk. "Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy to $499 per month." PR Newswire. prnewswire.com
  16. Novo Nordisk. "Ozempic List Price & Insurance Coverage Explained." NovoCare. novocare.com
  17. Novo Nordisk. "Rybelsus List Price & Insurance Coverage Explained." NovoCare. novocare.com
  18. GoodRx. "Liraglutide (Saxenda / Victoza) 2026 Prices, Coupons & Savings Tips." goodrx.com
  19. U.S. News & World Report. "Medicare GLP-1 Coverage 2026: Ozempic, Zepbound & Costs." health.usnews.com
  20. Novo Nordisk. "Patient Assistance Program (NNPAP)." novocare.com
  21. Healthline. "Is Compounded Semaglutide the Same as Ozempic?" 2025. healthline.com
  22. Novo Nordisk. "Wegovy Online Pharmacy and Savings." novocare.com
  23. STAT News. "Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy." March 9, 2026. statnews.com
  24. Markman Advisors. "What is the patent landscape for Novo Nordisk's semaglutide products: Ozempic, Wegovy and Rybelsus." February 2025. markmanadvisors.com
  25. Wired. "It's Shockingly Easy to Buy Off-Brand Ozempic Online." 2024. wired.com
  26. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Available at: novo-pi.com/ozempic.pdf
  27. Ozempic.com. Frequently Asked Questions: Ozempic Pen. Available at: ozempic.com/faqs/ozempic-pen.html
  28. Healthline. Ozempic: Uses, Dosage, Side Effects. Available at: healthline.com/health/drugs/ozempic
  29. Wegovy.com. Wegovy FAQs. Available at: wegovy.com/obesity/starting-wegovy/faq.html
  30. GoodRx. Wegovy and Zepbound Cost and Savings. Available at: goodrx.com/wegovy

Eli Lilly and brand resources

  1. WeightWatchers Editorial Team. Zepbound vs Mounjaro: What Is the Difference?, 2025. weightwatchers.com
  2. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release, December 11, 2025. investor.lilly.com
  3. Eli Lilly and Company. What to know about retatrutide. lilly.com. lilly.com
  4. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information. pi.lilly.com/us/zepbound-uspi
  5. Eli Lilly & Co. "Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients." Investor release. investor.lilly.com
  6. Eli Lilly & Co. "Mounjaro Savings & Resources." mounjaro.lilly.com
  7. Eli Lilly & Co. "Zepbound Coverage, Affordability, and Savings." zepbound.lilly.com
  8. Walmart Corporate. "LillyDirect and Walmart Pharmacy Launch First Retail Pick-Up Option With Direct-to-Consumer Pricing for Zepbound." corporate.walmart.com
  9. Eli Lilly. "Lilly lowers the price of Zepbound single-dose vials." lilly.com
  10. CNBC. "Eli Lilly cuts cash prices of Zepbound weight loss drug vials." December 1, 2025. cnbc.com
  11. Eli Lilly. Mounjaro and Zepbound (tirzepatide) Prescribing Information. Available at: lilly.com

Drugs.com

  1. Drugs.com. What are GLP-1 medications and how do they work?. Drugs.com, 2024. drugs.com
  2. Drugs.com. Semaglutide: Uses, Dosage, Side Effects, Brands. Drugs.com, 2026. drugs.com
  3. Drugs.com. Semaglutide dosage: usual adult dose for diabetes type 2. drugs.com/dosage/semaglutide

Consumer health, policy, and pricing

  1. Kaiser Family Foundation. "An Overview of Medicare Coverage and Spending on GLP-1s." kff.org
  2. GoodRx Research. "Tracking Insurance Coverage of Weight Loss Medications." goodrx.com
  3. Healthline. "GLP-1 Insurance Coverage for Weight Loss: 2026 Guide." healthline.com
  4. Kaiser Family Foundation. "Medicaid Coverage of and Spending on GLP-1s." kff.org
  5. U.S. News & World Report. "How to Get GLP-1 Drugs Without Insurance." health.usnews.com
  6. GoodRx. "GLP-1 Drug Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More." goodrx.com
  7. SingleCare. "Compounded semaglutide with B12: Benefits and risks." singlecare.com
  8. GoodRx. "Compounded Semaglutide: What Is It and Is It Safe?" 2025. goodrx.com
  9. AMCP. Frequently Asked Questions on GLP-1 Medications. Available at: amcp.org/resource/glp-1-faq

News and legal/regulatory analysis

  1. Rheumatology Advisor. TRIUMPH-4 Results: Retatrutide Cuts Weight and Knee OA Pain. December 2025. rheumatologyadvisor.com
  2. Academy of Managed Care Pharmacy. "Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s." amcp.org
  3. NPR. "Medicare to launch weight loss drug option in July with $50 copay." npr.org
  4. Stateline. "More states consider dropping GLP-1 weight loss drugs from Medicaid." stateline.org
  5. Fierce Healthcare. "FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market." February 2025. fiercehealthcare.com
  6. Foley & Lardner LLP. "FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products." April 2026. foley.com
  7. Foley & Lardner LLP. "GLP-1 Drugs: FDA Removes Semaglutide From the Drug Shortage List." February 2025. foley.com
  8. Harris Beach Murtha. "GLP-1 Weight-Loss Drugs Off Shortage List: Deadlines to Stop Compounding." 2025. harrisbeachmurtha.com
  9. Foley & Lardner LLP. "Compounded GLP-1 Drugs: Texas Judge Denies PI Motion." March 2025. foley.com
  10. NPR. "Eli Lilly sues companies selling alternative versions of its weight loss drug." April 23, 2025. npr.org
  11. Buchanan Ingersoll & Rooney. "State Board of Pharmacy: Ohio GLP-1 Compounders Be Vigilant." bipc.com
  12. Brookings Institution. "The Wild East of semaglutide." brookings.edu
  13. Holland & Knight. "Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth." June 2025. hklaw.com

Wikipedia

  1. Wikipedia contributors. Glucagon-like peptide-1. Wikipedia, 2025. en.wikipedia.org
  2. Wikipedia contributors. Semaglutide. Wikipedia, 2026. wikipedia.org
  3. Wikipedia contributors. Tirzepatide. Wikipedia, 2026. en.wikipedia.org
  4. Liraglutide. Wikipedia. Accessed May 2026. https://en.wikipedia.org/wiki/Liraglutide
  5. Wikipedia contributors. Retatrutide. en.wikipedia.org/wiki/Retatrutide
  6. Wikipedia. "Drug Quality and Security Act." wikipedia.org

Other sources

  1. Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. UK Government, 2025. gov.uk
  2. Prime Therapeutics. GLP-1 Pipeline Update: February 2026. Prime Therapeutics, 2026. primetherapeutics.com
  3. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020. insight.jci.org
  4. Volkow ND, Wang GJ. GLP-1 receptor agonists, dopamine, and food reward. Reviewed in Endocrinology, 2025. academic.oup.com
  5. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 2014. gubra.dk
  6. Deanfield J, Verma S, Scirica BM, et al. SELECT: Semaglutide and cardiovascular outcomes by baseline weight (subanalysis). Reported via TCTMD, 2024. tctmd.com
  7. University of Alabama at Birmingham. New UAB discovery on weight regain after stopping GLP-1 treatment (leptin sensitivity). UAB News, 2025. uab.edu
  8. Prime Therapeutics. GLP-1 Pipeline Update: 2025. Prime Therapeutics, 2025. primetherapeutics.com
  9. American Journal of Managed Care. FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight. AJMC, 2024. ajmc.com
  10. Aroda VR, Blonde L, Pratley RE. Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program. American Journal of Managed Care, 2021. ajmc.com
  11. Endocrinology Advisor. GLP-1 Interactions: Risks, Effects, and Recommendations. Endocrinology Advisor, 2025. endocrinologyadvisor.com
  12. Hauge C, Breitschaft A, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide on the Pharmacokinetics of Thyroxine after Dosing of Levothyroxine. Expert Opinion on Drug Metabolism & Toxicology, 2021. tandfonline.com
  13. Giblin JT, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. dom-pubs.onlinelibrary.wiley.com
  14. BioSpace. Lilly's Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges. December 2025. biospace.com
  15. Honest Care. Retatrutide FDA Approval Timeline & Status 2025-2027. findhonestcare.com
  16. Lengea Law. FDA Warns Companies Over Compounded Retatrutide. 2025. lengealaw.com
  17. Boehringer Ingelheim. EASi-HF Phase III trial in patients with HFpEF. boehringer-ingelheim.com
  18. NiceRx. Switching from semaglutide to tirzepatide dose conversion chart. nicerx.com/blog/switching-from-semaglutide-to-tirzepatide-dose-conversion-chart
  19. DiversifyRx. Compounded semaglutide and tirzepatide pharmacy guide for 503A practice. diversifyrx.com
  20. Klinic. Combining Intermittent Fasting with GLP-1 Medications: Safety Considerations. 2024. klinic.com
  21. National Association of Anorexia Nervosa and Associated Disorders (ANAD). GLP-1 Medications & Eating Disorders. anad.org
  22. Universal Drugstore. "Cheapest GLP-1 Options Online Without Insurance: A Complete Price Guide." universaldrugstore.com
  23. Doctronic. "GLP-1 Cost Without Insurance: Price Comparison Chart." doctronic.ai
  24. Trimi Health. "Cheapest Tirzepatide Providers 2026: All Options Ranked by Price." trytrimi.com
  25. Peterson-KFF Health System Tracker. "How do prices of drugs for weight loss in the U.S. compare to peer nations' prices?" healthsystemtracker.org
  26. Wellcare. "Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026." wellcare.com
  27. Military.com. "A VA Clinic Gave Veterans GLP-1s for Weight Loss. A Year Later, Everything Improved." military.com
  28. TRICARE / Express Scripts. "GLP-1 Medications (Diabetes and Weight Management)." militaryrx.express-scripts.com
  29. Lilly Cares Foundation. "How to Apply." lillycares.com
  30. PAN Foundation. "PAN opens first obesity copay fund to expand access to treatment." panfoundation.org
  31. GLP1Prices Canada. "Ozempic Price Canada 2026: Compare 33+ Pharmacies." glp1prices.ca
  32. Partnership for Safe Medicines. "FDA moves to restrict large-scale compounding of GLP-1s." May 4, 2026. safemedicines.org
  33. Frier Levitt. "FDA Warning Letters and the Hims-Novo Nordisk Deal." March 2026. frierlevitt.com
  34. National Association of Boards of Pharmacy. "Med Spas and GLP-1 Safety." nabp.pharmacy
  35. CNN. "Compounded semaglutide associated with at least 10 deaths." November 6, 2024. cnn.com
  36. US Pharmacopeia. "GLP1 Therapies Peptide Standards." usp.org
  37. Hall Render. "GLP-1 Gold Rush Meets Legal Reality: Novo Nordisk Challenges Compounded Alternatives." March 2026. hallrender.com
  38. IQVIA. "Off-patent semaglutide in 2026: the next revolution in anti-obesity treatment." July 2025. iqvia.com